A protected, separately financed operating company built to turn veterinary precision-health capabilities into focused commercial proof and an independently measurable strategic asset.
Veterinary rights, implementation support and evidence standards—without transferring parent-level IP or non-veterinary rights.
A dedicated team, budget and operating plan test clinic adoption, recurring revenue and species-specific evidence.
Committed capital, governance, reporting and commercial development—subject to verified capacity and clean closing conditions.
Authorize reciprocal diligence and a non-binding term-sheet process—not a merger, core-IP transfer, or automatic acquisition.
Practice revenue increased about 2.5% in 2025 while visits fell roughly 3%, reinforcing the need for measurable, workflow-compatible value.
Animal health is a practical entry point for integrated data, prevention and cross-sector collaboration—while remaining a distinct commercial vertical.
The initial business is deliberately narrow: veterinarian-mediated software, compatible diagnostics and evidence services. Broader device and One Health opportunities follow only after milestones.
Recurring workflow and patient-management services.
Compatible genomic and biomarker services.
Veterinary training and certification pathways.
Sponsored studies and governed real-world evidence.
Separate legal entity • dedicated budget • accountable management • ring-fenced contracts and data rights
Launch with 3–5 qualified practices and defined workflow, safety and support boundaries.
Measure adoption, paid conversion, data completeness, retention and willingness to renew.
Expand recurring software, assessments, labs, education and evidence partnerships.
Add future wearables, broader evidence services and One Health applications after review.
Can veterinary teams use the service in real workflows—and will practices and pet owners pay, remain engaged and renew?
Practice and patient-level software revenue anchors recurring economics.
One-time genomic assessment revenue supports onboarding and personalization.
Partner laboratory panels create repeat-service and data-integration economics.
Veterinary education builds adoption, quality and channel capability.
Governed studies and data services follow scale and protocol approval.
Wearables enter after commercial and technical gates—not as a launch dependency.
Illustrative model output; unaudited and dependent on funding, execution, clinic adoption, retention, partner performance and later expansion.
Release expansion capital only when adoption, unit economics, compliance and evidence gates are independently verified.
Capital funds a measured pilot. Adoption creates revenue. Revenue supports evidence. Evidence expands strategic value—and earns the right to scale.
Each cycle requires clean reporting, objective milestones and protected economics.
Fully diluted cap table, liabilities, litigation, transfer-agent reconciliation and market status.
Amount, source, timing, escrow, permitted uses and milestone releases documented.
Reserved matters, board rights, dilution protection, deadlock and related-party controls.
Field limits, assignment restrictions, security, audit, termination and transition support.
Mutual written approval for names, claims, forecasts, valuations and transaction statements.
Confirm scope, vehicle, diligence list and authorized communications.
Validate capitalization, liabilities, funding sources, IP authority and operating resources.
Build the 12–18 month pilot plan, budget, milestones and downside case.
Negotiate capitalization, governance, license, funding and data frameworks.